* Akoya Biosciences Inc AKYA.OQ reported a quarterly
adjusted
loss of 21 cents per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -26 cents. The mean expectation of
eight analysts for the quarter was for a loss of 20 cents per
share. Wall Street expected results to range from -26 cents
to -16 cents per share.
* Revenue fell 25.1% to $18.81 million from a year ago;
analysts
expected $25.42 million.
* Akoya Biosciences Inc's reported EPS for the quarter was a
loss
of 21 cents.
* The company reported a quarterly loss of $10.53 million.
* Akoya Biosciences Inc shares had risen by 15.1% this
quarter and
lost 35.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 0.2%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the advanced
medical
equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for Akoya Biosciences
Inc is 4.00
This summary was machine generated from LSEG data November 15 at
02:09 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.20 -0.21 Missed
Jun. 30 2024 -0.29 -0.27 Beat
Mar. 31 2024 -0.29 -0.48 Missed
Dec. 31 2023 -0.27 -0.22 Beat